XOMA Royalty Acquires Pulmokine for $20 Million
Deal News | Dec 02, 2024 | Broadview Ventures
XOMA Royalty has acquired Pulmokine for $20 million, a move aimed at bolstering its portfolio with royalty and milestone interest in Seralutinib, which is currently in Phase 3 trials. The acquisition is significant for XOMA as it adds a valuable pharmaceutical asset that could potentially lead to impactful respiratory therapy solutions. Moreover, the support from Broadview Ventures in this transaction underscores the PE firm's role in aiming to back innovative biotech endeavors. This strategic acquisition might signal XOMA's intent to strengthen its downstream revenue streams via milestone payments linked to successful clinical and regulatory outcomes of Seralutinib.
Sectors
- Pharmaceuticals
- Private Equity
- Biotechnology
Geography
- United States – XOMA and Pulmokine are based in the United States, making it the key geographical region for this acquisition.
Industry
- Pharmaceuticals – The acquisition involves Seralutinib, a pharmaceutical asset in Phase 3 clinical trials, underscoring the focus on drug development and therapeutic solutions.
- Private Equity – Broadview Ventures' involvement highlights the role of private equity firms in facilitating financial backing for transactions in the biotech and pharmaceutical sectors.
- Biotechnology – Pulmokine is a biotech company, and the acquisition focuses on a therapeutic candidate, emphasizing the biotech industry aspect.
Financials
- 20,000,000 – The acquisition price paid by XOMA to acquire Pulmokine.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| XOMA Royalty | Acquirer | Company | A company engaged in acquiring pharmaceutical royalties and milestone interests. |
| Pulmokine | Target Company | Company | The biotech company being acquired, which holds interest in the therapeutic asset Seralutinib. |
| Broadview Ventures | Private Equity Firm/Supporter | Company | A private equity firm providing financial support for the acquisition. |